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HIV/AIDS and its treatment often alter body composition and result in poorer physical functioning. The aim of this study was to
determine the eﬀects of a moderate-intensity exercise program on body composition and the hormones and cytokines associated
with adverse health outcomes. HIV-infected males (N = 111) were randomized to an exercise group (EX) who completed 6
weeks of moderate-intensity exercise training, or to a nonintervention control group (CON). In pre- and postintervention, body
composition was estimated via DXA, peak strength was assessed, and resting blood samples were obtained. There was a decrease in
salivary cortisol at wake (P = 0.025) in the EX and a trend (P = 0.07) for a decrease 1 hour after waking. The EX had a significant
increase in lean tissue mass (LTM) (P < 0.001) following the intervention. Those in the EX below median body fat (20%) increased
LTM (P = 0.014) only, while those above 20% decreased fat mass (P = 0.02), total fat (N = 0.009), and trunk fat (P = 0.001),
while also increasing LTM (P = 0.027). Peak strength increased between 14% and 28% on all exercises in the EX group. These data
indicate that 6 weeks of moderate-intensity exercise training can decrease salivary cortisol levels, improve physical performance,
and improve body composition in HIV-infected men.

1. Introduction
Over 33.3 million people are living with HIV-1 [1]. Since it
was introduced in the mid to late 1990s, highly active antiretroviral therapy (HAART) has increased the time from HIV
infection to acquired immunodeficiency syndrome (AIDS)
diagnosis by 3 years and life expectancy of those with AIDS
by up to 15 years [2]. In fact, these advances have allowed
those living with HIV-1, and receiving treatment, to have life
expectancies similar to uninfected persons with lifestyles that
include smoking, heavy drinking, and obesity [3]. Mortality
rates of HIV-infected persons dropped drastically within 18
months after the introduction of HAART, from 29.4 deaths

per 100 person years to 8.8 deaths per 100 person years [4].
In fact, in younger (∼30 years of age) persons with favorable
disease markers (i.e., high CD4+ cell counts and low viral
load) survival has been estimated at 31 years, with 45%
of deaths attributable to non-HIV-related conditions, such
as cardiovascular disease and cancer [5]. This brings about
new challenges in treating persons with HIV-1, changing the
focus from purely survival to improving quality of life by
decreasing risk factors for other chronic conditions. Thus, it
is important to understand how exercise training, which has
been shown to be beneficial at reducing risk factors for both
cardiovascular disease and cancer in uninfected populations,
aﬀects those persons living with HIV-1.
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While HAART has been able to significantly increase the
survival of HIV-infected patients, HAART-associated cardiometabolic risks are increasing. HAART regimens, specifically those using protease inhibitors (PI), have been shown
to cause lipodystrophy as well as metabolic changes that
result in an increased risk for cardiovascular disease. It has
been previously observed that patients with lipodystrophy
show increases in total serum and low-density lipoprotein
cholesterol, triglycerides, and insulin resistance [6].
A complication of HIV disease that has remained, even
with the implementation of HAART, is HIV/AIDS-related
wasting, which eﬀects nearly 20% of those living with
HIV-1 [7]. HIV/AIDS-associated wasting is characterized by
reductions in fat mass, lean body mass (LBM), muscular
strength, and functional performance and is associated with
disease progression [8].
The pathophysiology behind these somatic changes
increases the risk for cardiometabolic diseases possibly due
to the proinflammatory process exhibited. Further, there
is a strong association between HIV/AIDS-related wasting
and increased mortality [9], impaired functional status [10],
accelerated disease progression [11], and a declining ability
to carry out activities of daily living [12]. HIV-infected persons also demonstrate an increased susceptibility to infection
[13] and show a progressive depletion of metabolically active
tissue near death [14].
The mechanisms behind HIV-associated wasting appear
to be abnormal levels of circulating catabolic and anabolic
hormones, cytokines, and binding proteins. Cortisol, which
is elevated in HIV-infected persons [15–17], is a potent
catabolic hormone, which increases rates of protein degradation and slows protein synthesis rates, especially in skeletal
muscle [18]. Serum cortisol levels also appear to be the best
predictor for insulin resistance followed by interleukin-6 (IL6) in persons with inflammatory conditions [19]. Insulin-like
growth factor 1 (IGF-1) is the mechanism by which growth
hormone (GH) influences skeletal muscle and is a potent
regulator of muscle mass [20]. Those persons suﬀering from
HIV/AIDS wasting frequently demonstrate GH resistance,
which manifests itself in increased GH levels and decreased
IGF-1 levels, and may be attributed to malnutrition [21].
Insulin-like growth factor binding protein 3 (IGFBP-3) is
the major IGF-1 binding protein in circulation and can
extend the half-life of circulating IGF-1 from minutes to
several hours thereby maintaining constant IGF-1 levels.
HIV-1 infection increases the proteolysis of IGFBP-3, thus
decreasing IGFBP-3 levels and in turn reducing the amount
of IGF-1 in circulation [22]. Another hormone of interest is
testosterone, which is low in 30–50% of HIV-infected men
[23] and is of significance because testosterone is a potent
regulator of skeletal muscle mass that acts, via multiple
pathways, to increase protein synthesis [24–26].
Inflammation is a prominent component in HIV/AIDS
wasting and is also linked to cardiometabolic conditions.
While inflammation is a necessary process for muscle generation [27], it may be catabolic if found in excess levels for
prolonged periods. Cytokines of note in this inflammatory
process include tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1-β), and IL-6. However, IL-6 may also
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exhibit anti-inflammatory functions, as it can inhibit TNFα and IL-1-β [28]. TNF-α has been associated with muscle
wasting in many diseased populations [29–31] including
HIV-1 [32] and HIV-infected persons have been shown to
have elevated TNF-α levels [33, 34].
Elevated levels of these proinflammatory markers are also
known to be associated with an increased risk of chronic disease. Relationships have consistently been identified among
atherosclerosis and cardiovascular disease with greater levels
of C-reactive protein (CRP), TNF-α, and IL-6 [35, 36].
Further, IL-1-β has been implicated in numerous disease
states including rheumatoid arthritis [37], atherosclerosis
[38], and type I diabetes [39]. Studies looking at patients
with metabolic disorders have also shown increased levels of
IL-6 and CRP among type II diabetics, obese individuals, and
patients experiencing metabolic syndrome [40–42].
An emerging treatment that has the potential to improve
the circulating abnormalities (e.g., low anabolic hormone
levels and high proinflammatory markers) of those with
HIV-1 is exercise training. Before further discussing the
potential beneficial eﬀects of exercise in HIV-infected populations, it should first be recognized that research has shown
exercise to be safe in this population. Low- to moderateintensity exercise does not alter CD4 cell counts or viral load,
nor does it increase the prevalence of opportunistic infection
[43]. Additionally, no reports of adverse side eﬀects to exercise interventions have been reported.
Resistance exercise training is known to increase skeletal
muscle mass and muscular strength in numerous healthy
and clinical populations regardless of gender, age, or race
[44]. Aerobic exercise is also known to prevent or manage
chronic diseases such as insulin resistance, cardiovascular
disease, and cancer. This could possibly be a result of the
protective eﬀects aerobic exercise has shown to have against
inflammation. Studies have repeatedly shown the benefits
of aerobic exercise against inflammation by decreasing CRP,
IL-6, TNF-α, among other proinflammatory markers [45–
47]. Further, limited data in HIV-infected populations have
shown similar eﬀects. Progressive resistance exercise alone
has produced significant increases in muscular strength and
lean body mass in HIV-infected persons with and without
wasting [48–50]. Similarly, the combination of resistance
exercise and aerobic exercise has also increased strength
and lean mass in HIV-infected populations [51–53] and
produced transient increases in anabolic hormones [54].
Thus, it appears that resistance exercise training has the
potential to be a complimentary therapy to pharmacological
treatments for maintaining and increasing lean body mass
and muscular strength in HIV-infected persons.
However, what remains to be seen is the eﬀect of a lower
dose (lower volume and lesser intensity) of combined resistance and aerobic exercise on body composition, strength
and inflammation in HIV-infected persons. Further, this type
of intervention may improve subject compliance. Therefore,
the aim of this study was to determine the eﬀect of an
American College of Sports Medicine- (ACSM-) based lowvolume, moderate-intensity resistance and aerobic exercise
training program on the strength, body composition, and
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circulating hormone and inflammatory cytokine profile in a
sample of HIV-infected men.

2. Methods
2.1. Sample. HIV-infected men over 18 years of age free
of any known opportunistic infections, currently receiving antiretroviral therapy (ART), and physically able to
complete the exercise intervention were recruited from
local HIV/AIDS service organizations in the Columbia, SC
metropolitan area. Flyers were placed in the waiting areas of
clinics, and research team members enlisted the assistance of
HIV/AIDS case workers in recruiting subjects.
Individuals who met the above criteria were excluded
from the study following a physician’s screening if (1) their
medical history revealed current opportunistic infection(s),
(2) they were found to be currently using, or had used in
the past, hormone therapy, (3) they scored 5 or greater on
the Drug Abuse Screening Test (DAST) and/or the Michigan
Alcohol Screening Test (MAST), (4) they were found to be
currently involved in a structured exercise program, or (5)
any contraindications for graded exercise stress testing, as
specified by the American College of Sports Medicine [55]
were identified.
2.2. Procedure. All procedures, including testing and exercise
training, were completed in the Clinical Research Laboratory
in the Department of Exercise Science at the University
of South Carolina. After signing the informed consent
statement, subjects were assigned an identification number
and then were assisted in completing a demographic data
sheet (age, race, CDC disease stage, and current health status)
and a cardiovascular risk factor survey that addressed current
medications (including HIV medications), family history
of cardiovascular disease, smoking habits, physical activity
habits, any significant health concerns (other than HIV infection), and other pertinent health information. Medical
personnel then reviewed the risk factor survey, and if no
contraindications for exercise stress testing were identified,
subjects were cleared to receive a graded treadmill stress
test (GXT). Following successful completion of the GXT,
subjects were randomized, using a random number table,
to the intervention group (EX) or a nonintervention control
(CON) group. Following the completion of study requirements, those randomized to the CON group (who did not
receive intervention) then received the aerobic and resistance
exercise intervention twice weekly for six weeks. The Oﬃce
of Research Compliance at the University of South Carolina
approved the study and its procedures.
2.3. Body Composition Assessment. Dual energy X-ray absorptiometry (DXA) scans (GE Medical Instruments, Madison, WI) for body composition were administered before the
first exercise session and within 1-week following the last
exercise session. A state certified DXA technician calibrated
the equipment, performed each scan, and analyzed the
results yielding lean mass and fat mass data, both for the
entire body and by region.
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2.4. Peak Strength Assessment. All subjects had peak strength
determined on upper body resistance exercises (chest press,
lat pull down) and lower body resistance exercises (leg
extension, leg curl). Subjects were instructed on the proper
techniques for each exercise and then were given one warmup set of 8–12 repetitions (minimal weight was selected for
this set) to become comfortable with the exercise. Subjects
were then instructed to complete three repetitions on each
exercise with the most weight possible while maintaining
proper form. Weight selection was based on subject input
and observation by the investigator. Since this population
was untrained and unfamiliar with resistance training, a
three-repetition maximum (3-RM) was used instead of the
standard 1-RM, which has been used by others in clinical
populations [7, 56, 57]. Using the standard conversion set
forth by Brzycki [58], a 3-RM is approximately 94% of the
1-RM. Sixty percent of this 3-RM was then used as the initial
weight for the resistance exercises.
2.5. Design. A randomized control group experimental
design was used to determine the eﬀects of moderateintensity exercise training on circulating hormone, cytokine,
and binding protein levels in HIV-infected men. All EX
subjects were scheduled to attend 2 exercise sessions per week
during the 6-week study. Exercise sessions were separated by
at least 48 hours to allow for adequate recovery. Subjects
had to complete 10 of the 12 sessions over the study
duration to be included in the final analysis. Following the
last exercise or control session, subjects were given three
salivettes to take home. They were instructed to collect saliva
samples immediately after waking (W), 1 hour after waking
(W+1), and 2 hours after waking (W+2) on the day they
were scheduled to return for posttesting. On the pre- and
posttesting days, subjects were instructed to arrive fasted and
were scheduled to arrive at the same time of the day so as to
avoid hormonal variation due to normal cycles. Blood was
collected and saliva samples were returned at this time.
2.6. Exercise Intervention. Those subjects randomized to the
EX group completed 30 minutes of aerobic exercise training,
on a treadmill or stationary cycle, in the intensity range
of 60–75% of their age predicted maximum heart rate
(208 × 0.7 (age in years)) twice weekly, for 6 weeks. Heart
rate during exercise was monitored using Polar Heart Rate
Monitors. Each exercise session consisted of a 3–5 minute
warm up period followed by 30 minutes of training within
the prescribed intensity range, and then a 3 to 5 minute
cool down. Treadmill speed and grade were adjusted during
each session to keep subjects within their prescribed intensity
range.
Following aerobic exercise subjects completed upper
body and lower body resistance training exercises. Movements targeting the chest, upper back, triceps, upper anterior
and posterior legs, and lower legs were performed on
resistance training machines, while movements targeting
the biceps brachii and deltoids were performed using free
weights. Sets were alternated in a circuit such that one
particular muscle group was not exercised in consecutive
sets. Subjects were given approximately one minute recovery
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time between sets. Resistance was adjusted so subjects
could complete 12 repetitions per set of each exercise while
maintaining proper form. As strength increased, resistance
was changed so as to keep the subjects at the prescribed
training intensity. Exercise training sessions were separated
by at least 48 hours to allow for recovery and a trained
exercise physiologist monitored all exercise sessions.
2.7. Sample Analysis
2.7.1. Saliva. Saliva was collected using salivettes, which
contain small cotton swabs. Subjects were given the cotton
swabs and instructed on appropriate placement of the swab
in their mouths. The saliva was recovered by inserting a
saturated cotton swab into the salivette and centrifuging the
container at a relative centrifuge force of 39,000 kg for 5
minutes. The particulate free saliva sample was then obtained
from the bottom of the salivette and saliva aliquots were
frozen and stored at −80◦ C until analyzed. Salivary cortisol
(CORT) was analyzed using a colorimetric sandwich ELISA
(R&D Systems, Minneapolis, MN, USA).
2.7.2. Blood. Blood (3 mL) was collected at the specified
times into serum separator tubes via venipuncture in an
antecubital vein in the lower arm. All blood samples were
taken with subjects in a seated position. The remaining whole
blood was then centrifuged at a relative centrifuge force
of 39,000 kg for 20 minutes, and the resulting supernatant
was removed, alliquoted, and frozen at −80◦ C until needed
for analysis. Commercially available colorimetric sandwich
enzyme immunoassays (R&D Systems, Minneapolis, MN,
USA) were used for the analysis of IL-6, sTNFrII, IGF1, IGFBP-3, and GH. IL-1β was measured with a solid
phase enzyme amplified sensitivity immunoassay (BioSource
Europe, Nivelles, Belgium).
2.7.3. Urine. Urine was collected in urine collection containers over 24-hour periods in which no exercise was
performed, both before and after the 6-week exercise training
period. Subjects were given the urine collection container
and instructed on the proper procedures for collection.
After waking on the day in which the urine was to be
collected, the first urination of the day was not collected,
but each subsequent urination for the next 24-hours was
to be collected in the urine collection container. Subjects
were instructed to keep the urine cool until returned to the
research facility, at which time it was alliquoted and frozen at
−80◦ C until needed for analysis.
GH and CORT are released in a pulsatile fashion into
the circulation throughout the day [59]. Therefore, to
better estimate the total amount of hormone released, these
hormones were measured in one milliliter samples of the
urine, which provides the amount per milliliter. This value
was then multiplied by the volume of urine produced during
the day to yield the total amount produced over a 24-hour
period. Urinary CORT and GH were both analyzed using a
colorimetric sandwich ELISA (R&D Systems, Minneapolis,
MN, USA). Normal urine production varies greatly between
individuals, and is influenced by many factors. For the
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purposes of this study, only those subjects who collected
at least 500 mL of urine (1/3 the mean production for
participants) at each time point were included in the final
analysis.
2.8. Quantification of Exercise Protocol. Caloric expenditure
of physical work was quantified during the aerobic exercise
portion of the exercise protocol using the formula published
by Keytel et al. [60]. This method estimates caloric expenditure per minute of activity based on the heart rate recorded
during the previous minute and includes the age, gender,
body weight, and VO2 max of the subject. The calories
expended per minute were then multiplied by the duration
of the exercise session yielding the total calories burned
per session. There is no accepted method of estimating
the caloric expenditure of resistance exercise, therefore the
resistance portion of the exercise protocol was quantified
based on total weight moved per session.
2.9. Measurement of Physical Activity. The Physical Activity
Scale for the Elderly (PASE) was used to assess physical
activity levels to determine if the aerobic and resistance
exercise program had an eﬀect on leisure and occupational
physical activity levels in the exercise group. The PASE, which
asks the participant to recall their activities over the previous
7 days, was administered at the pretesting session and again
at the posttesting session.
2.10. Statistical Analysis. Repeated measures analysis of
variance (ANOVA) was used to compare salivary cortisol
within groups. Tukey post hoc analysis of treatment means
was used to identify diﬀerences between groups. All other
within-group variables were assessed using a paired t-test
and comparison of variables between groups was done with
an unpaired t-test. The significance level of all statistical tests
was set at α = .05. All values are expressed as mean ±
standard error (SE). Upon completion of the initial analysis,
the exercise group data was divided at the median body fat
percentage, which was 20% body fat, and the data from these
two groups was analyzed.

3. Results
3.1. Demographic Data. One hundred eleven (111) HIVinfected males were cleared for study participation while 17
subjects were excluded at screening based on the previously
mentioned criteria. After oversampling of the control group
and subject attrition, 59 subjects were randomly assigned
to the control group and 52 subjects were randomized to
the EX group. Forty (40) subjects completed the exercise
intervention and 36 subjects in the control group finished the
study. Body composition data were collected on 31 subjects
in the exercise group and 27 persons in the control group.
Hormone data were collected on 16 subjects in the exercise
group and 27 persons in the control group. Demographic
data for each group are presented in Tables 1 and 2.
3.2. Quantification of Exercise Protocol. The number of
calories burned per week of aerobic exercise was not diﬀerent
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Table 1: Demographic data for subjects who completed the training
study.
Variable
Age
African American
Caucasian
T-cell count
HIV + symptomatic
HIV − symptomatic
AIDS
Did not answer
Excellent health
Good health
Fair health
Poor health
Did not answer

Control (CON)
group (N = 10)
46.6 ± 1.5
6
4
406 ± 76 (8)
6
1
2
1
0
7
2
0
1

HIV status is based on 1993 CDC criteria.

Table 2: Demographic data for subjects who completed body composition assessment.
Exercise group
(N = 31)
43.6 ± 1.3
20
10
1
28
3
17
4
7
3
6
18
4
1
2

Variable
Age
African American
Caucasian
Other
ART Yes
ART No
HIV + symptomatic
HIV − symptomatic
AIDS
Did not answer
Excellent health
Good health
Fair hearth
Poor health
Did not answer

control Group
(N = 27)
45.1 ± 1.5
17
10
0
25
2
19
1
4
3
2
18
6
0
1

HIV status is based on 1993 CDC criteria. “ART Yes” refers to those subjects
who reported taking at least 1 antiretroviral therapy during the study period.

between weeks; it ranged from a high of 523.3 ± 41.1 calories
during week 4 to a low of 467.3 ± 54.5 calories during week
6. There was a diﬀerence in the total weight moved during
each week of the resistance exercise portion of the protocol,
with total pounds increasing over time. As expected, the
total pounds lifted during week 6 was greater than week 1
(P < .001), week 2 (P < .001), week 3 (P < .001), and week
4 (P = .02). Similarly, the pounds lifted during week 5 were
greater than week 1 (P < .001), week 2 (P < .001), and week
3 (P = .005).

7000

∗

6000
Cortisol (pg/mL)

Exercise (MOD)
group (N = 16)
43.1 ± 1.3
12
4
373 ± 60 (7)
8
3
3
2
2
9
2
1
2

Resting salivary cortisol

#

5000
4000
3000
2000
1000
Wake

Wake +1
Time

Wake +2

Pre-EX rest
Post-EX rest

Figure 1: Salivary cortisol in exercise group. Salivary cortisol in
MOD group (N = 13) subjects measured immediately after waking,
1 hour after waking, and 2 hours after waking. ∗ Indicates diﬀerence
from Pre-EX test with P < .05. # Indicates diﬀerence from Pre-EX
test with P = .07.

3.3. Physical Activity Measurement. Following the 6-week
moderate-intensity exercise intervention, there was no
change in leisure and occupational physical activity levels (as
measured by the PASE) in either the exercise group (P = .38)
or the control group (P = .42). Additionally, there were
no diﬀerences in baseline leisure and occupational physical
activity levels between the exercise and control groups (P =
.29).
3.4. Hormone and Cytokine Variables. There was a decrease
in salivary cortisol at wake in the exercise group following the
intervention, and there was a trend for a decrease one hour
after waking in the exercise group (see Figure 1). There were
no other changes from pre- to postintervention in either the
exercise group or the control group in any of the hormone
and cytokine variables measured (see Table 3).
3.5. Body Composition. At study initiation, there were no
diﬀerences between groups regarding any of the body composition variables, including body mass index (see Table 4).
Following the training period, the exercise group had an
increase in lean tissue mass, while no change was seen in
the control group (see Figure 2). Neither group exhibited
changes in fat mass, total percentage of body fat, trunk
percentage of fat, or any other body composition variable
measured.
The exercise group was then divided at the median
body fat percentage: those with a preintervention body
fat above 20% (+20), and those below 20% (−20) (see
Table 5). Following the intervention, subjects in the +20
group exhibited a significant increase in lean tissue mass
(P = .027), as did the −20 group (P = .014). Further, the +20
group decreased total fat mass (P = .02), percentage of total
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Table 3: Resting hormone values and normal ranges.

Variable
IL-6 (pg/mL)
IL-1-β (pg/mL)
sTNFrII (ng/mL)
IGF-1 (ng/mL)
IGFBP-3 (ng/mL)
Growth hormone (ng/day)
Cortisol (μg/mL)
Testosterone (saliva) (pg/mL)

MOD group (N = 16)
Pre
Post
P value
3.6 ± 1.0
3.1 ± 0.6
.6
7.5 ± 1.7
.9
5.9 ± 0.5
2.4 ± 0.4
.6
2.2 ± 0.3
132 ±10.8
.4
128 ±10.5
1934 ± 871
.7
1897 ± 224
7.1 ± 1.2
.3
8.9 ± 1.7
61.2±9
.3
55.6 ± 5.9
65.1 ± 4.7
.06
101.1 ± 16.4

CON group (N = 10)
Pre
Post
P value
3.6 ± 1.0
6.7 ± 2.0
.08
6.2 ± 0.6
6.1 ± 0.5
.3
2.6 ± 0.5
2.5 ± 0.5
.4
118 ± 10.7
137 ±17.5
.2
1824 ± 247
1769 ± 218
.6
15.1 ± 7.1
18.9 ± 11.8
.5
45.5 ± 7.2
57.7 ± 8.8
.1
95.1 ± 29.3
61.6 ± 8.9
.3

Normal range
1–10
0–2.5
0.28–7
100–500
835–3778
1–81
10–100
30–100

Table 4: Body composition of exercise and control group subjects.

Height (m)
Mass (kg)
BMI (m/kg)
LTM (kg)
FM (kg)
% Total body fat
% Fat trunk
% Fat ARM
% FatLEG
LTM ARM (kg)
LTM LEG (kg)
LTM TRK (kg)
∗

Exercise group (N = 31)
Pre
Post
1.76 ± 0.01
1.76 ± 0.01
71.8 ± 2.1
71.4 ± 2.1
23.1
23.2
56.3 ± 1.1
57.1 ± 1.1
14.3 ± 1.9
14.1 ± 1.9
18.5 ± 1.9
18.2 ± 1.8
21.7 ± 2.2
21.1 ± 2.1
13.7 ± 1.8
13.7 ± 1.8
16.3 ± 1.9
15.9 ± 1.9
6.8 ± 0.2
6.9 ± 0.2
18.4 ± 0.5
18.8 ± 0.5
27.2 ± 0.7
27.4 ± 0.6

P value
—
.08
<.001∗
.295
.182
.058
1.0
.347
.244
.107
.430

Control group (N = 27)
Pre
Post
1.74 ± 0.02
1.74 ± 0.02
72.5 ± 2.5
72.9 ± 2.5
24.0
24.1
55.9 ± 1.15
55.9 ± 1.6
14.1 ± 1.7
13.9 ± 1.7
18.1 ± 1.8
18.0 ± 1.8
21.7 ± 2.1
21.7 ± 2.1
14.1 ± 1.5
14.1 ± 1.7
16.6 ± 1.7
16.0 ± 1.7
6.8 ± 0.2
6.9 ± 0.2
18.3 ± 0.4
18.4 ± 0.4
27.3 ± 0.9
27.1 ± 0.7

P value
—
.847
.915
.178
.317
.239
.683
.847
1.0
.811
.695

Indicates a significant change within groups from pre- to postintervention.

body fat (P = .009), and percentage of trunk fat (P = .001).
No changes in these variables were seen in the −20 group.
However, the −20 group did show an increase in total body
mass (P = .007). The −20 group also had a significant
increase in BMI (P = .007) following the intervention, while
no change was observed in the +20 group (see Figures 3 and
4).
3.6. Peak Strength. Following the intervention, both the
exercise and the control groups showed an increase in lower
body strength. The exercise group had an increase in peak
leg extension strength (P < .001) and an increase in peak
leg curl strength (P = .001), while the control group also
had increase in leg extension (P = .03) and leg curl strength
(P = .006). The control group, however, did not show a
change in lat pull down strength or chest press strength,
while the exercise group did improve both lat pull down
(P < .001) and chest press strength (P < .001) following the
intervention (see Table 6).
3.7. Girth. There were no detectable changes in the exercise
group for arm girth, leg girth, or chest girth following the
training session. Additionally, there were no changes in arm
girth, leg girth, or chest girth in the control group. Further,
there were no diﬀerences between the two groups in any of
the three girth measurements.

4. Discussion
Recent work has suggested that aerobic and resistance exercise interventions can cause beneficial physiologic responses
and adaptations in HIV-infected populations [48, 61–63].
Specifically, we have shown that ACSM-based moderateintensity aerobic and resistance exercise can cause transient
increases in anabolic factors (GH) and decreases in catabolic
factors (sTNFrII). Thus, the goal of this study was to determine if 6-weeks of a similar ACSM-based exercise program
caused body composition, hormonal, and performance benefits. The rationale for testing this intervention is that (1) it
is of shorter duration than other published works, (2) it is of
lower intensity than other published works, (3) it combines
both aerobic and resistance exercise, (4) it is an industryrecognized exercise prescription that benefits cardiovascular
health in the apparently uninfected population, and (5) it has
already been shown to stimulate positive humoral changes in
an HIV-infected population [61].
There have been few original randomized controlled
studies that have examined the eﬀects of progressive resistance exercise interventions in HIV+ populations [48, 49, 64,
65]. Fewer yet are studies combining progressive resistance
training and aerobic training [51–53]. However, results have
been encouraging, with increases in total body mass [48, 51,
52, 65], lean mass [48, 49, 51], and peak strength [48, 49, 51–
53, 65] being reported.
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Figure 2: Lean tissue, fat, and total body mass of exercise and control group subjects. Body composition measurements taken via DXA in
the exercise (N = 31) and control (N = 27) group before (pre) and after (post) the 6-week exercise intervention. ∗ Indicates a significant
change in the exercise group from Pre- to post-test.

Table 5: Body composition of exercise subjects above and below 20% body fat. Body composition variables, and within group changes,
of exercise subjects as they are stratified into groups of above 20% total body fat (+20) and below 20% total body fat (−20), based on
preintervention DXA testing.

Height (m)
Mass (kg)
BMI (m/kg)
LTM (kg)
FM (kg)
% Total Body Fat
% Fat Trunk
% Fat ARM
% FatLEG
LTM ARM (kg)
LTM LEG (kg)
LTM TRK (kg)
∗

Pre
1.76 ± 0.01
78.1 ± 2.7
25.4 ± 0.9
56.4 ± 1.7
23.4 ± 2.4
28.6 ± 1.5
33.7 ± 1.3
22.3 ± 2.4
24.3 ± 2.7
6.9 ± 0.3
18.4±.0.6
27.3 ± 1.1

+20% Fat group (N = 14)
Post
1.76 ± 0.01
78.0 ± 3.0
25.3 ± 1.0
57.1 ± 1.7
22.71 ± 2.4
27.7 ± 1.6
32.2 ± 1.4
22.0 ± 2.4
24.0 ± 2.8
6.9 ± 0.3
18.6 ± 0.6
27.8 ± 0.9

Indicates a significant change from pre- to postintervention within groups.

−20% Fat group (N = 17)

P value
—
.665
.664
.027∗
.02∗
.009∗
.001∗
.619
.269
.746
.660
.268

Pre
1.74 ± 0.02
65.8 ± 2.4
21.3 ± 0.8
56.3 ± 1.5
6.7 ± 0.9
10.1 ± 1.1
11.8 ± 1.5
6.6 ± 0.8
9.7 ± 1.2
6.8 ± 0.3
18.5 ± 0.7
27.0 ± 0.8

Post
1.74 ± 0.02
66.7 ± 2.4
21.6 ± 0.9
57.1 ± 1.5
7.0 ± 1.0
10.4 ± 1.1
12.1 ± 1.5
6.8 ± 1.1
9.3 ± 0.9
6.9 ± 0.3
19.1 ± 0.8
27.0 ± 0.7

P value
—
.007∗
.007∗
.014∗
.143
.269
.299
.757
.578
.189
.014∗
.898

8

ISRN AIDS
Stratified MOD group total body mass

Stratified MOD group lean tissue mass
Lean tissue mass (kg)

Total body mass (kg)

∗

80

65

∗

59

∗#

58
57
56
55

Pre

Pre

Post

Post
Time

Time
(a)

(b)

Stratified MOD group fat mass
#
Fat mass (kg)

25

5
Pre

Post
Time

+20
−20

(c)

Figure 3: Lean tissue, fat, and total body mass of exercise subjects above and below 20% body fat. Body composition measurements taken
via DXA in the +20 (N = 14) and −20 (N = 17) exercise groups before (pre) and after (post) the 6-week exercise intervention. ∗ Indicates a
significant change in the −20 group; # indicates a significant change in the +20 group.
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Figure 4: Total percentage of body fat and trunk percentage of body fat in exercise subjects above and below 20% Body Fat. Body fat
percentage of measurements taken via DXA in the +20 (N = 14) and −20 (N = 14) exercise groups before (pre) and after (post) the 6-week
exercise intervention. # Indicates a change in the +20 group.
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Table 6: Strength changes in exercise and control group subjects. Peak strength results, and within group changes, for the exercise and
control groups.
Exercise
Leg Extension
Leg Curl
Lat Pull
Chest Press
∗

Pre
153.8 ± 13.3
120.4 ± 9
132.4 ± 7.4
118.5 ± 6.2

Exercise Group (n = 17)
Post
185.3 ± 13.5
143.2 ± 7.9
148.8 ± 7.2
135.3 ± 7

P Value
<.001∗
.001∗
<.001∗
<.001∗

Pre
140 ± 11.3
105.5 ± 6.1
120.9 ± 7.6
111.6 ± 8.7

Control Group (n = 11)
Post
161.4 ± 13.9
128.2 ± 7.1
124.1 ± 7.4
109.6 ± 6.1

P Value
.03∗
.006∗
.532
.782

Indicates a significant change from pre to post test.

The majority of these interventions have required subjects to participate in three exercise sessions per week, and
with the exception of one study [65], all have been 8–16
weeks in duration, with 12 weeks being the most common
[48, 51–53]. The interventions have generally required the
subjects to start resistance exercise at 60% of their 1-RM,
then increased resistance to anywhere from 80% to 90% 1RM near the end of the study.
4.1. Body Composition. The eﬀect of exercise training on
total body mass in HIV-infected persons has been ambiguous, with some showing an increase [48, 52, 65], while others
[49, 51] have failed to detect a change. We did not show
a diﬀerence in total body mass following training. Results
similar to our findings were reported by Grinspoon and
colleagues [51] and Roubenoﬀ and colleagues who did not
show an exercise eﬀect on total body mass following 8 weeks
of exercise training at intensities of 80% 1-RM and higher.
Conversely, Spence et al. [65] reported a 1.7 kg increase in
body weight following 6 weeks of three weekly progressive
resistance exercise sessions. However, these subjects had
recently recovered from Pneumocystis carinii pneumonia
and were examined before HAART was available. Similarly,
Lox and colleagues [52] reported a 2.2 kg increase in total
body mass following 12 weeks of three weekly progressive
resistance exercise sessions in men receiving ART. A 2.2 kg
increase in total body mass was also seen by Bhasin et al.
[48] in men (all receiving ART) following 16 weeks (3 sessions/wk.) of progressive resistance exercise with resistance
progressing from 60% 1-RM to 90%. The discrepancy in total
body mass changes following exercise is diﬃcult to interpret
for the following reasons: subjects in all the above studies had
similar total body mass at study initiation, study duration
did not appear to have an eﬀect as both shorter [65] and
longer [48, 52] durations showed increases, lower progressive
resistance exercise intensities [65] and higher intensities [48]
produced changes, and changes were seen in those who were
on ART [48] and who were not [52, 65].
Our detection of a 0.8 kg increase in lean tissue mass is
consistent with the findings of others. Grinspoon and colleagues [51] (2.3 kg), Bhasin and colleagues [48] (2.0 kg), and
Roubenoﬀ and colleagues [49] (1.8 kg) all showed significant
increases in lean tissue mass using DXA, while Lox [52]
showed a 2.3 kg increase in nonfat tissue using the skin-fold
technique. While our change is significant, it appears to be
less than the other studies mentioned. However, it should

be noted that the subjects in our study trained at a lower
intensity, less frequently, and for a shorter time period than
the other studies showing increases in lean tissue mass. Of
the other three studies mentioned, only Roubenoﬀ et al. [49]
(8 weeks) trained subjects for less than 12 weeks, and the
reported change in lean tissue mass (1.8 kg) was less than the
other studies (2.3 kg, 2.3 kg, and 2.0 kg) of longer duration.
Additionally, of the other studies mentioned, only Lox et al.
trained subjects at a lower intensity (60% 1-RM), but still
observed similar lean tissue mass gains. It appears that ART
does not influence lean tissue mass gains, as those subjects
not using ART [52] and those subjects using ART [48, 49, 51]
both showed an increase in lean tissue mass. However, it
appears that the length of the intervention may aﬀect lean
tissue mass gains, in that interventions of longer duration
may result in larger lean tissue mass gains.
To our knowledge, we are the first to stratify subjects
based on preintervention body fat percentage. The rationale
for this action was based on our finding of a significant
increase in lean tissue mass in the exercise group, with no
changes in total body mass or fat mass. When looking at
the exercise group in this fashion it can be seen that the
+20 did not change total body mass and the −20 gained
total body mass, thus explaining the no change in total body
mass the entire exercise group. Similarly, the +20 group
lost total fat mass while the −20 group did not change in
these variables, so again no overall change was seen. This
suggests a diﬀerential eﬀect of exercise training based on
preintervention body composition.
The only group to show a regional change in LTM was
the −20 group, who exhibited an increase in leg lean tissue
mass. Using CT, Grinspoon et al. [51] showed an increase in
thigh muscle area, and using MRI, Bhasin et al. [48] found
and increase in thigh muscle volume. Though no direct
mass measurements were taken, Spence et al. [65] showed an
increase in thigh girth. Thus, it seems consistent across the
literature that resistance training is capable of increasing lean
tissue mass in the legs. However, what remains uncertain is
why we only found an increase in leg lean tissue mass in the
−20 group, and not the +20 group.
Only Roubenoﬀ et al. [49] reported a decrease in total
fat mass following their exercise intervention. This change
in fat, however, could stem from the extended exercise time
prescribed in the study (20 minutes of aerobic training in
addition to 1 hour of resistance training). Our study, along
with the remainder of the studies included in this discussion,
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only prescribed exercise regimens lasting approximately 60
minutes. The 0.92 ± 2.22 kg decrease in total fat mass
reported by Roubenoﬀ et al. [49] is similar to the 0.73 ±
0.3 kg decrease seen in our study. However, the decrease in
our study was only observed in men with body fat above
20%. A possible explanation for this could be that the
subjects in the Roubenoﬀ et al. [49] study had 20.3 ± 2.3 kg
of body fat at study initiation, while our exercise group as a
whole had only 14.3 ± 1.9 kg, and our +20 group had 23.4 ±
2.4 kg. Therefore, when similar populations are compared, it
appears that the exercise eﬀect on total body fat is consistent.
Further, our finding of a decrease in trunk fat in the +20
group suggests additional health benefits, as trunk fat is
associated with numerous cardiometabolic diseases which
are common in HIV disease [5].
4.2. Physical Functioning. Following our exercise training
program, those in the exercise group showed significant
increases in all four strength exercises tested: leg extension
(25 ± 6.2%), leg curl (27.6 ± 9.5%), lat pull (13.8 ± 3.3%),
and chest press (14.3 ± 1.8%). Bhasin et al. [48] (29–
36%), Roubenoﬀ et al. [49] (31–50%), and Lox et al. [52]
also showed increased strength using conventional isotonic
testing equipment. Rigsby et al. [53] showed upper and lower
body strength increases using a hydraulic dynamometer.
Only Grinspoon et al. [51] failed to show a change in strength
following the exercise intervention; however, this study used
isometric testing which, as the authors suggest, may not have
detected a strength change if it existed [66]. These findings
indicate that, even at moderate intensities, resistance exercise
training can cause an increase in strength in HIV-infected
men, independent of ART usage.
4.3. Resting Hormones and Cytokines. The only change
detected within groups at the conclusion of the intervention
was a decrease in salivary cortisol from pre- to posttest in
the exercise group at the waking time point, and there was
a trend for a decrease one hour after waking. There were no
other changes detected in CORT, TEST, IGF-1, IGFBP-3, GH,
IL-6, STNFrII, or IL-1-β in the CON or exercise groups.
In light of the changing landscape of HIV disease,
namely, the shift towards a chronic disease, it is important
to determine how HIV-infected persons who have yet to
develop AIDS respond to exercise training. This population
is now dealing with the same chronic diseases as their noninfected counterparts, specifically cancer and cardiometabolic
diseases which are the leading non-HIV related causes of
death [5]. While certain causes of these diseases (physical
inactivity, stress, poor diet, etc.) undoubtedly are involved
in their development in HIV-infected persons, the chronic
immune activation and inflammatory state found in these
persons may also be contributing factors [67]. Thus, it is
prudent to examine exercise training in this population given
the eﬀect of exercise on body composition, hormone, and
cytokine profiles, as well as the established benefits of exercise
in reducing the risk for developing cardiometabolic diseases
and cancer.
There is no research outlining the eﬀects of exercise training on resting hormone and cytokine levels in HIV-infected
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persons. However, data does exist in other populations
suggesting that exercise can influence many of the anabolic
and catabolic factors implicated in the altered metabolic
environment of those with HIV [68, 69]. The measurement
of resting cytokines in the circulation is diﬃcult, thus
little research in this area is available. One of the major
factors influencing cytokine levels is immune function, thus,
whether the individual is currently ill or recovering from
illness, cytokine levels are not “normal” [70]. Further, it
appears that the primary impact of exercise on cytokine levels
occurs during, and immediately following exercise sessions.
IL-6 levels have been shown to increase immediately
following exercise that is not of suﬃcient intensity to induce
muscle damage [71, 72] and this increase may provide antiinflammatory eﬀects [28]. This is the proposed rationale for
the association that has been discovered between increased
physical activity levels and decreased systemic inflammation
in healthy persons [73–76]. Though we did see elevated
resting levels of one inflammatory marker (IL-1-β) in our
population, we did not see a change in IL-6 following
exercise. It should be noted that IL-6 levels (3.6 ± 0.7 pg/mL)
were found to be within a normal range in our sample and we
have previously shown that IL-6 levels rise acutely following
exercise [54], thus fitting with the hypothesis that the antiinflammatory eﬀects of exercise in this population are the
result of acute changes.
We anticipated a change in sTNFrII and IL-1-β following
the exercise intervention given that basal levels in HIVinfected populations have been shown to be elevated and
acute exercise appears to decrease these levels [77]. We
found sTNFrII to be within normal range in our population,
thereby potentially explaining our lack of a detectable change
because these levels were not elevated. By contrast, we found
resting IL-1-β to be well above normal, which would fit with
other literature. However, the theoretical anti-inflammatory
eﬀects of exercise are dependent upon another cytokine, IL6, which we also found not to change following our training.
Thus, if IL-6 did not increase, it would not directly block
TNF-α and IL-1-β production, nor would it inhibit these
inflammatory cytokines by inducing production of the antiinflammatory agents IL-10 and IL-1ra production.
Normal daily urine production is highly variable and
can range 700–2000 mL/day, with males typically producing
approximately 1500 mL/day. The subjects in our study
averaged 772 ± 118 mL/day, with a range from 300 mL to
2800 mL. We had access to our subjects only during the
testing days, and the exercise sessions, thus in order to get
a representation of total GH production we measured GH
levels in 24-hour urine samples. We found an average of 8.6 ±
1.2 ng/day in our subjects, which fits within the 1–81 ng/day
reported in healthy populations [78]. The consensus in the
literature is that basal GH levels do not change following
exercise training in healthy populations [69, 79, 80]. Therefore, our lack of change fits with the current literature.
Our resting IGF-1 levels were in the lower range of
normal values for uninfected populations. Our results show
no change in resting levels of IGF-1 following the exercise
intervention. This finding, in combination with the reported
presence of a change in elderly men [81] that often suﬀer the
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same decrease in lean tissue mass as HIV-infected persons,
makes the absence of a change in resting IGF-1 levels in
our population somewhat surprising. However, other clinical
populations have failed to show a change in IGF-1 levels
following exercise training, and some have even reported a
decrease [82].
In addition to the lack of a change in IGF-1, the major
binding protein, IGFBP-3, was also unchanged following our
6-week moderate-intensity exercise training intervention.
The eﬀects of individual exercise sessions on circulating
IGFBP-3 levels are just now being realized, and the eﬀect
of exercise training on resting IGFBP-3 is largely unknown.
Individual exercise sessions of moderate-intensity exercise
appear to increase IGFBP-3 levels [83]. Combined with
the increased IGFBP-3 proteolysis reported in HIV-infected
persons, we anticipated an increase in resting IGFBP-3 levels.
However, we did not see a change in IGFBP-3 following our
intervention, and we found IGFBP-3 levels to be normal.
It appears that training status is a factor in the response of
resting cortisol levels to exercise training. Prolonged exercise
training does not appear to influence cortisol levels in trained
persons [84, 85]; however, cortisol was lower following
training in many populations, including sedentary adult
males. Thus, it was unexpected that we did not see decreases
in 24-hour cortisol levels following exercise training in our
exercise naı̈ve population. Additionally, it should be noted
that resting cortisol levels in our population were within
a normal range. However, our untrained population did
exhibit a decrease in salivary cortisol following training at the
wake time point and showed a trend for a decrease 1 hour
after waking.
The literature clearly demonstrates that persons infected
with HIV are prone to multiple hormone and cytokine
abnormalities. However, the use of ART, which slows disease
progression, can also normalize some of the hormone
and cytokine levels in this population [86]. Thus, in our
population receiving ART, and in whom a majority classified
themselves as HIV-positive and asymptomatic, it is logical to
see mostly normal hormone and cytokine profiles. Therefore,
it is possible that these normal circulating levels explain the
lack of changes following the exercise intervention.
A limitation that aﬀects many training studies, not just
those involving HIV-infected persons, is subject retention
and adherence to exercise. The high incidence of opportunistic infections in this population adds diﬃculty to
subject retention, as does the poverty and lack of reliable
transportation that so often is present in this population.
Further, the stigma of HIV that is pervasive in this country
dissuades many HIV-infected persons from responding to
research opportunities. Given these circumstances, plus the
3–5 weekly exercise sessions required in other studies, poor
retention rates and small sample sizes can be explained.
However, our 77% retention rate suggests that (1) our
sampled population was not burdened with the problems of
other studied HIV-infected populations, (2) our twice weekly
sessions were manageable, and (3) our moderate-intensity
exercise regimen lessened the fatigue and muscle soreness
that accompanies higher intensity regimens.
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5. Conclusion
This research further strengthens the evidence for the safety
and eﬃcacy of prescribing resistance and aerobic exercise
to HIV-infected men. No adverse events were reported, and
there was a very low attrition rate. The only circulating
hormone or cytokine we found in abnormal levels was IL1-β, which was more than twice as high as the upper limit
of the normal range. Aside from IL-1-β, our findings of
“normal” circulating levels of hormones and cytokines in our
population may explain our inability to detect changes in all
these variables, except cortisol. It may be that those HIVinfected persons experiencing chronic low-grade inflammation may respond diﬀerently to the prescribed exercise
intervention. Even in healthy populations, it is common
to not detect changes in these variables, thus our HIVinfected population may be responding to exercise training
the same as uninfected persons. Also, these data suggest
that the benefits of exercise training in HIV-infected men
using ART may be attributable to the transient decrease in
resting CORT, the accumulation of hormone and cytokine
changes following individual exercise sessions, or to factors
yet to be investigated. Additionally, these results indicate that
low-volume moderate-intensity exercise training, consistent
with ACSM guidelines, is suﬃcient to produce beneficial
physiological adaptations and the resulting performance
improvements (increase in upper and lower body strength)
in HIV-infected men receiving ART. Further, this study is the
first to report diﬀerential eﬀects of exercise training based
on preintervention body composition. Both the +20 and
−20 groups realized the health benefits of increasing lean
tissue mass, without gaining fat mass, while the +20 group
also experienced the health benefit of losing trunk fat. Taken
together, these results provide evidence for the eﬀectiveness of combined moderate-intensity aerobic and resistance
exercise training at decreasing the risk for cardiometabolic
diseases and increasing lean tissue mass; thus, strongly
suggesting its inclusion in the standardized treatment plan
of those infected with HIV-1.

Acknowledgments
Support for this work was provided by the American College
of Sports Medicine Carl V. Gisolfi Memorial Research Fund
and NIH/NCMHD (1 P20 MD001770-030003). The views
expressed are those of the authors and should not be assumed
to be an endorsement of the ACSM.

References
[1] UNIADS, “UNAIDS global report on the AIDS epidemic,”
Tech. Rep., 2010.
[2] R. P. Walensky, A. D. Paltiel, E. Losina et al., “The survival
benefits of AIDS treatment in the United States,” Journal of
Infectious Diseases, vol. 194, no. 1, pp. 11–19, 2006.
[3] M. Zwahlen, R. Harris, M. May, R. Hogg, D. Costagliola, F. de
Wolf et al., “Mortality of HIV-infected patients starting potent
antiretroviral therapy: comparison with the general population in nine industrialized countries,” International Journal of

12

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

ISRN AIDS
Epidemiology, vol. 38, no. 6, Article ID dyp306, pp. 1624–1633,
2009.
F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining
morbidity and mortality among patients with advanced
human immunodeficiency virus infection,” New England
Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998.
R. S. Braithwaite, A. C. Justice, C. C. H. Chang et al., “Estimating the proportion of patients infected with HIV who will die
of comorbid diseases,” American Journal of Medicine, vol. 118,
no. 8, pp. 890–898, 2005.
S. Grinspoon and A. Carr, “Cardiovascular risk and body-fat
abnormalities in HIV-infected adults,” New England Journal of
Medicine, vol. 352, no. 1, pp. 48–62, 2005.
C. A. Wanke, M. Silva, T. A. Knox, J. Forrester, D. Speigelman,
and S. L. Gorbach, “Weight loss and wasting remain common
complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy,”
Clinical Infectious Diseases, vol. 31, no. 3, pp. 803–805, 2000.
A. J. S. Coats, “Origin of symptoms in patients with cachexia
with special reference to weakness and shortness of breath,”
International Journal of Cardiology, vol. 85, no. 1, pp. 133–139,
2002.
A. Schwenk, A. Beisenherz, K. Romer, G. Kremer, B.
Salzberger, and M. Elia, “Phase angle from bioelectrical
impedance analysis remains an independent predictive marker
in HIV-infected patients in the era of highly active antiretroviral treatment,” American Journal of Clinical Nutrition, vol. 72,
no. 2, pp. 496–501, 2000.
S. Grinspoon, C. Corcoran, D. Rosenthal et al., “Quantitative
assessment of cross-sectional muscle area, functional status,
and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome,” Journal of Clinical
Endocrinology and Metabolism, vol. 84, no. 1, pp. 201–206,
1999.
P. Guenter, N. Muurahainen, G. Simons et al., “Relationships
among nutritional status, disease progression, and survival in
HIV infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 10, pp. 1130–1138, 1993.
M. C. Gelato and R. A. Frost, “IGFBP-3: functional and
structural implications in aging and wasting syndromes,”
Endocrine, vol. 7, no. 1, pp. 81–85, 1997.
M. S. Dworkin and J. M. Williamson, “AIDS wasting syndrome: trends, influence on opportunistic infections, and
survival,” Journal of Acquired Immune Deficiency Syndromes,
vol. 33, no. 2, pp. 267–273, 2003.
D. P. Kotler, A. R. Tierney, J. Wang, and R. N. Pierson, “Magnitude of body-cell-mass depletion and the timing of death from
wasting in AIDS,” American Journal of Clinical Nutrition, vol.
50, no. 3, pp. 444–447, 1989.
A. Biglino, P. Limone, B. Forno et al., “Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection,” European Journal of Endocrinology,
vol. 133, no. 2, pp. 173–179, 1995.
N. Christeﬀ, S. Gharakhanian, N. Thobie, W. Rozenbaum, and
E. A. Nunez, “Evidence for changes in adrenal and testicular
steroids during HIV infection,” Journal of Acquired Immune
Deficiency Syndromes, vol. 5, no. 8, pp. 841–846, 1992.
J. M. Villette, P. Bourin, C. Doinel et al., “Circadian variations
in plasma levels of hypophyseal, adrenocortical and testicular
hormones in men infected with human immunodeficiency
virus,” Journal of Clinical Endocrinology and Metabolism, vol.
70, no. 3, pp. 572–577, 1990.
R. Breitkreutz, J. Wagner, M. Tokus et al., “Flux of amino
acids and energy substrates across the leg in weight-stable

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]
[27]

[28]

[29]

[30]

[31]
[32]

[33]

[34]

HIV-infected patients with acute opportunistic infections:
indication of a slow protein wasting process,” Journal of
Molecular Medicine, vol. 79, no. 11, pp. 671–678, 2001.
M. Lehrke, U. C. Broedl, I. M. Biller-Friedmann et al.,
“Serum concentrations of cortisol, interleukin 6, leptin and
adiponectin predict stress induced insulin resistance in acute
inflammatory reactions,” Critical Care, vol. 12, no. 6, article
no. R157, 2008.
M. Hameed, R. W. Orrell, M. Cubbold, G. Goldspink, and S.
D. R. Harridge, “Expression of IGF-I splice variants in young
and old human skeletal muscle after high resistance exercise,”
Journal of Physiology, vol. 547, no. 1, pp. 247–254, 2003.
S. Grinspoon, C. Corcoran, K. Lee et al., “Loss of lean body
and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and
wasting,” Journal of Clinical Endocrinology and Metabolism,
vol. 81, no. 11, pp. 4051–4058, 1996.
M. C. Gelato and R. A. Frost, “IGFBP-3: functional and
structural implications in aging and wasting Syndromes,”
Endocrine, vol. 7, no. 1, pp. 81–85, 1997.
A. S. Dobs, “Androgen therapy in AIDS wasting,” Bailliere’s
Clinical Endocrinology and Metabolism, vol. 12, no. 3, pp. 379–
390, 1998.
R. C. Griggs, D. Halliday, W. Kingston, and R. T. Moxley, “Eﬀect of testosterone on muscle protein synthesis in
myotonic dystrophy,” Annals of Neurology, vol. 20, no. 5, pp.
590–596, 1986.
R. J. Urban, Y. H. Bodenburg, C. Gilkison et al., “Testosterone administration to elderly men increases skeletal muscle
strength and protein synthesis,” American Journal of Physiology, vol. 269, no. 5, part 1, pp. E820–E826, 1995.
F. C. W. Wu, “Endocrine aspects of anabolic steroids,” Clinical
Chemistry, vol. 43, no. 7, pp. 1289–1292, 1997.
T. A. Robertson, M. A. L. Maley, M. D. Grounds, and
J. M. Papadimitriou, “The role of macrophages in skeletal
muscle regeneration with particular reference to chemotaxis,”
Experimental Cell Research, vol. 207, no. 2, pp. 321–331, 1993.
R. Schindler, J. Mancilla, S. Endres, R. Ghorbani, S. C.
Clark, and C. A. Dinarello, “Correlations and interactions
in the production of interleukin-6 (IL-6), IL-1, and tumor
necrosis factor (TNF) in human blood mononuclear cells: IL6 suppresses IL-1 and TNF,” Blood, vol. 75, no. 1, pp. 40–47,
1990.
S. D. Anker and M. Rauchhaus, “Insights into the pathogenesis
of chronic heart failure: immune activation and cachexia,”
Current Opinion in Cardiology, vol. 14, no. 3, pp. 211–216,
1999.
M. O. Farber and E. T. Mannix, “Tissue wasting in patients
with chronic obstructive pulmonary disease, the acquired
immune deficiency syndrome, and congestive heart failure,”
Neurologic Clinics, vol. 18, no. 1, pp. 245–262, 2000.
M. J. Tisdale, “Wasting in cancer,” Journal of Nutrition, vol.
129, no. 1, supplement, pp. 243S–246S, 1999.
L. L. Moldawer and F. R. Sattler, “Human immunodeficiency
virus-associated wasting and mechanisms of cachexia associated with inflammation,” Seminars in Oncology, vol. 25, no. 1,
supplement 1, pp. 73–81, 1998.
D. R. Luke, B. J. McCreedy, T. P. Sarnoski et al., “Phase I/II
study of pentoxifylline with zidovudine on HIV-1 growth in
AIDS patients,” International Journal of Clinical Pharmacology
Therapy and Toxicology, vol. 31, no. 7, pp. 343–350, 1993.
N. Wig, P. Anupama, S. Singh et al., “Tumor necrosis factor-α
levels in patients with HIV with wasting in South Asia,” AIDS
Patient Care and STDs, vol. 19, no. 4, pp. 212–215, 2005.

ISRN AIDS
[35] P. T. Larsson, S. Hallerstam, S. Rosfors, and N. H. Wallén,
“Circulating markers of inflammation are related to carotid
artery atherosclerosis,” International Angiology, vol. 24, no. 1,
pp. 43–51, 2005.
[36] P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “Creactive protein, the metabolic syndrome, and risk of incident
cardiovascular events: an 8-year follow-up of 14 719 initially
healthy American women,” Circulation, vol. 107, no. 3, pp.
391–397, 2003.
[37] J. H. Schwab, S. K. Anderle, R. R. Brown, F. G. Dalldorf,
and R. C. Thompson, “Pro- and anti-inflammatory roles
of interleukin-1 in recurrence of bacterial cell wall-induced
arthritis in rats,” Infection and Immunity, vol. 59, no. 12, pp.
4436–4442, 1991.
[38] G. Ku, C. E. Thomas, A. L. Akeson, and R. L. Jackson, “Induction of interleukin 1β expression from human peripheral
blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid,” Journal of Biological Chemistry, vol. 267, no. 20,
pp. 14183–14188, 1992.
[39] T. Mandrup-Poulsen, S. Helqvist, J. Molvig, L. D. Wogensen,
and J. Nerup, “Cytokines as immune eﬀector molecules in
autoimmune endocrine diseases with special reference to
insulin-dependent diabetes mellitus,” Autoimmunity, vol. 4,
no. 3, pp. 191–218, 1989.
[40] U. N. Das, “Is obesity an inflammatory condition?” Nutrition,
vol. 17, no. 11-12, pp. 953–966, 2001.
[41] J. M. Fernández-Real and W. Ricart, “Insulin resistance and
chronic cardiovascular inflammatory syndrome,” Endocrine
Reviews, vol. 24, no. 3, pp. 278–301, 2003.
[42] A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and
P. M. Ridker, “C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus,” Journal of the American
Medical Association, vol. 286, no. 3, pp. 327–334, 2001.
[43] W. D. Dudgeon, K. D. Phillips, C. M. Bopp, and G. A. Hand,
“Physiological and psychological eﬀects of exercise interventions in HIV disease,” AIDS Patient Care and STDs, vol. 18,
no. 2, pp. 81–98, 2004.
[44] B. F. Hurley, R. A. Redmond, R. E. Pratley, M. S. Treuth, M.
A. Rogers, and A. P. Goldberg, “Eﬀects of strength training on
muscle hypertrophy and muscle cell disruption in elder men,”
International Journal of Sports Medicine, vol. 16, no. 6, pp. 378–
384, 1995.
[45] M. L. Kohut, D. A. McCann, D. W. Russell et al., “Aerobic
exercise, but not flexibility/resistance exercise, reduces serum
IL-18, CRP, and IL-6 independent of β-blockers, BMI, and
psychosocial factors in older adults,” Brain, Behavior, and
Immunity, vol. 20, no. 3, pp. 201–209, 2006.
[46] M. L. M. P. Jorge, V. N. de Oliveira, N. M. Resende et al.,
“The eﬀects of aerobic, resistance, and combined exercise
on metabolic control, inflammatory markers, adipocytokines,
and muscle insulin signaling in patients with type 2 diabetes
mellitus,” Metabolism: Clinical and Experimental, vol. 60, no.
9, pp. 1244–1252, 2011.
[47] E. S. Ford, “Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults,” Epidemiology,
vol. 13, no. 5, pp. 561–568, 2002.
[48] S. Bhasin, T. W. Storer, M. Javanbakht et al., “Testosterone
replacement and resistance exercise in HIV-infected men
with weight loss and low testosterone levels,” Journal of the
American Medical Association, vol. 283, no. 6, pp. 763–770,
2000.
[49] R. Roubenoﬀ, A. McDermott, L. Weiss et al., “Short-term progressive resistance training increases strength and lean body

13

[50]

[51]

[52]

[53]

[54]

[55]
[56]

[57]

[58]

[59]
[60]

[61]

[62]

[63]

[64]

[65]

mass in adults infected with human immunodeficiency virus,”
AIDS, vol. 13, no. 2, pp. 231–239, 1999.
R. Roubenoﬀ and I. B. Wilson, “Eﬀect of resistance training on
self-reported physical functioning in HIV infection,” Medicine
and Science in Sports and Exercise, vol. 33, no. 11, pp. 1811–
1817, 2001.
S. Grinspoon, C. Corcoran, K. Parlman et al., “Eﬀects of
testosterone and progressive resistance training in eugonadal
men with AIDS wasting: a randomized, controlled trial,”
Annals of Internal Medicine, vol. 133, no. 5, pp. 348–355, 2000.
C. L. Lox, E. McAuley, and R. S. Tucker, “Aerobic and
resistance exercise training eﬀects on body composition,
muscular strength, and cardiovascular fitness in an HIV-1
population,” International Journal of Behavioral Medicine, vol.
3, no. 1, pp. 55–69, 1996.
L. W. Rigsby, R. K. Dishman, A. W. Jackson, G. S. Maclean, and
P. B. Raven, “Eﬀects of exercise training on men seropositive
for the human immunodeficiency virus-1,” Medicine and
Science in Sports and Exercise, vol. 24, no. 1, pp. 6–12, 1992.
W. D. Dudgeon, K. D. Phillips, J. L. Durstine et al., “Individual
exercise sessions alter circulating hormones and cytokines
in HIV-infected men,” Applied Physiology, Nutrition and
Metabolism, vol. 35, no. 4, pp. 560–568, 2010.
ACSM’S Guidelines for Exercise Testing and Prescription, Lippincott, Williams & Wilkins, Philadelphia, Pa, USA, 2005.
A. Menkes, S. Mazel, R. A. Redmond et al., “Strength training
increases regional bone mineral density and bone remodeling
in middle-aged and older men,” Journal of Applied Physiology,
vol. 74, no. 5, pp. 2478–2484, 1993.
S. Welle, C. Thornton, and M. Statt, “Myofibrillar protein
synthesis in young and old human subjects after three months
of resistance training,” American Journal of Physiology, vol.
268, no. 3, part 1, pp. E422–E427, 1995.
M. Brzycki, “Strength Testing—predicting a one-rep max from
reps to fatigue,” Journal of Physical Education, Recreation, and
Dance, vol. 64, no. 1, pp. 88–90, 1993.
E. N. Marieb, “Endocrine system,” in Human Anatomy &
Physiology, pp. 603–643, Pearson Education, 2006.
L. R. Keytel, J. H. Goedecke, T. D. Noakes et al., “Prediction
of energy expenditure from heart rate monitoring during
submaximal exercise,” Journal of Sports Sciences, vol. 23, no.
3, pp. 289–297, 2005.
W. D. Dudgeon, K. D. Phillips, J. L. Durstine et al., “Individual
exercise sessions alter circulating hormones and cytokines
in HIV-infected men,” Applied Physiology, Nutrition and
Metabolism, vol. 35, no. 4, pp. 560–568, 2010.
W. D. Dudgeon, K. D. Phillips, J. A. Carson, R. B. Brewer, J.
L. Durstine, and G. A. Hand, “Counteracting muscle wasting
in HIV-infected individuals,” HIV Medicine, vol. 7, no. 5, pp.
299–310, 2006.
G. A. Hand, K. D. Phillips, W. D. Dudgeon, G. W. Lyerly, J.
L. Durstine, and S. E. Burgess, “Moderate intensity exercise
training reverses functional aerobic impairment in HIVinfected individuals,” AIDS Care, vol. 20, no. 9, pp. 1066–1074,
2008.
D. Agin, D. Gallagher, J. Wang, S. B. Heymsfield, R. N. Pierson,
and D. P. Kotler, “Eﬀects of whey protein and resistance
exercise on body cell mass, muscle strength, and quality of life
in women with HIV,” AIDS, vol. 15, no. 18, pp. 2431–2440,
2001.
D. W. Spence, M. L. A. Galantino, K. A. Mossberg, and S. O.
Zimmerman, “Progressive resistance exercise: eﬀect on muscle
function and anthropometry of a select AIDS population,”

14

[66]

[67]
[68]

[69]

[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

ISRN AIDS
Archives of Physical Medicine and Rehabilitation, vol. 71, no.
9, pp. 644–648, 1990.
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